Scott Capen, MD
Family Medicine · Greenfield, INNPI 1386646925
Payments from drug & device makers
Across 230 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$732
- Novo Nordisk$419
- Pfizer$397
- GSK$238
- Novartis$235
- Astellas Pharma US Inc$222
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,521100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $732 |
| Novo Nordisk | 32 | $419 |
| Pfizer | 25 | $397 |
| GSK | 15 | $238 |
| Novartis | 15 | $235 |
| Astellas Pharma US Inc | 11 | $222 |
| Lilly USA, LLC | 11 | $205 |
| Supernus Pharmaceuticals, Inc. | 17 | $193 |
| AstraZeneca | 8 | $122 |
| Exact Sciences | 6 | $115 |
| Arbor Pharmaceuticals, Inc. | 2 | $105 |
| Amgen | 6 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $80 |
| Corium, LLC | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Abbott | 2 | $35 |
| Ironshore Pharmaceuticals Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Averitas Pharma Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Merck | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Circassia Inc. | 1 | $11 |
| Mayne Pharma Commercial LLC | 1 | $8 |
How this compares
$3,521 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 222 | $210,261 |
| JardianceEmpagliflozin | 134 | $145,302 |
| MounjaroTirzepatide | 114 | $125,684 |
| OzempicSemaglutide | 102 | $117,990 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 141 | $117,489 |
| XareltoRivaroxaban | 124 | $116,535 |
| RybelsusSemaglutide | 73 | $97,327 |
| Repatha SureclickEvolocumab | 83 | $91,455 |
| TrulicityDulaglutide | 37 | $71,920 |
| FarxigaDapagliflozin Propanediol | 64 | $64,600 |
| MyrbetriqMirabegron | 35 | $38,394 |
| JanuviaSitagliptin Phosphate | 33 | $36,245 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $31,442 |
| LinzessLinaclotide | 21 | $29,378 |
| Spiriva RespimatTiotropium Bromide | 31 | $24,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $419 | $215,317175 claims |
| PfizerEliquis | $397 | $210,261222 claims |
| Lilly USA, LLCMounjaro, Trulicity | $205 | $197,604151 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix | $238 | $170,041231 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $122 | $75,73477 claims |
| MerckJanuvia, Lagevrio (Eua) | $15 | $49,83052 claims |
| Astellas Pharma US IncMyrbetriq | $222 | $38,39435 claims |
| AbbVieLinzess | $732 | $29,37821 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $6,031608 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Greenfield
- Talessa PowellGreenfield$1.4M
- Thomas O'ConnorGreenfield$228K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.